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Frederic Blanchard1,2,3, Françoise Redini1,2,3,4, Dominique Heymann1,2,3,4*
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Abstract
Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic
lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic
methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine kinase inhibitor, was originally developed for the
treatment of chronic myeloid leukemia. Several studies revealed that imatinib mesylate inhibits osteoclast differentiation
through the M-CSFR pathway and activates osteoblast differentiation through PDGFR pathway, two key cells involved in the
vicious cycle controlling the tumour development. The present study investigated the in vitro effects of imatinib mesylate
on the proliferation, apoptosis, cell cycle, and migration ability of five osteosarcoma cell lines (human: MG-63, HOS; rat:
OSRGA; mice: MOS-J, POS-1). Imatinib mesylate was also assessed as a curative and preventive treatment in two syngenic
osteosarcoma models: MOS-J (mixed osteoblastic/osteolytic osteosarcoma) and POS-1 (undifferentiated osteosarcoma).
Imatinib mesylate exhibited a dose-dependent anti-proliferative effect in all cell lines studied. The drug induced a G0/G1 cell
cycle arrest in most cell lines, except for POS-1 and HOS cells that were blocked in the S phase. In addition, imatinib
mesylate induced cell death and strongly inhibited osteosarcoma cell migration. In the MOS-J osteosarcoma model, oral
administration of imatinib mesylate significantly inhibited the tumour development in both preventive and curative
approaches. A phospho-receptor tyrosine kinase array kit revealed that PDGFRa, among 7 other receptors (PDFGFRb, Axl,
RYK, EGFR, EphA2 and 10, IGF1R), appears as one of the main molecular targets for imatinib mesylate. In the light of the
present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in
osteosarcoma according to the tyrosine-kinase receptor status of patients.
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Introduction
Osteosarcoma is a rare bone tumour mainly affecting young
patients (peak of incidence around 18 years old), defined by the
presence of tumour cells producing an osteoid matrix [1]. The
current therapeutic sequence for high-grade osteosarcoma was
proposed by Rosen et al in the 1970s and is now internationally
accepted [2]. This treatment is based on neo-adjuvant chemo-
therapy, delayed en-bloc wide resection, and adjuvant chemo-
therapy adapted to the histologic profile assessed on tumour tissue
removed during surgery. In spite of the fact that the development
of polychemotherapy has clearly improved the survival and the
quality of life of patients, the 5-year event-free survival has
remained at a plateau of 60–70% of patients with non-metastatic
osteosarcoma for over the last 40 years [3]. Nevertheless, in the last
10 years, better knowledge of oncogenic processes in osteosarcoma
has led to the development of new therapeutic approaches based
on single new drugs or administered in combination with
conventional chemotherapy [4].
Targeting intra-cellular signaling or metabolic pathways appear
as promising therapeutic approaches. For instance, mevalonate
pathway may be an interesting target in osteosarcoma. Thus, the
combination of apomine and lovastatine which targets the
mevalonate pathways significantly reduced tumour progression
in osteosarcoma-bearing mice compared to single treatment which
had no effect at the doses used [5]. The mTOR inhibitor
ridaforolimus has been studied in a phase II trial of patients with
advanced bone sarcomas and this study revealed improved
progression-free survival in advanced sarcomas including osteo-
sarcoma [6]. Moriceau et al. demonstrated recently that RAD001
(everolimus) a new oral mTOR inhibitor, inhibited osteosarcoma
cell proliferation and its combination with zoledronic acid reduced
tumour development in murine models of mixed osteoblastic/
osteolytic or undifferentiated osteosarcoma [7]. Similarly, NVP-
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BEZ235, a dual pan-PI3K-mTOR inhibitor, exhibits anti-
proliferative effects in a panel of osteosarcomas and showed
synergistic activity with chemotherapeutic agents and with other
small signaling inhibitors [8]. In contrast, targeting Src, a tyrosine
kinase which activates tumour cell-motility and invasion showed
interesting anti-proliferative and pro-apoptotic activity in osteo-
sarcoma cell lines but did not exert any activity in vivo [9].
Imatinib mesylate (Gleevec) is an orally active tyrosine kinase
inhibitor with activity against a large panel of tyrosine kinase
protein including bcr/abl, c-kit, MCSF receptor (cFMS) and the
PDFG receptor among others [10]. Its clinical success is
demonstrated by its current use as a first-line therapy for patients
with bcr-abl-positive chronic myeloid leukemia [11] and in
gastrointestinal stromal cell tumours characterized by activating
mutations of c-kit [12]. In addition, imatinib mesylate exerts direct
effects on bone cells. It inhibits osteoclast-resorbing activity by
increasing mature osteoclast apoptosis and targeting the MCF
receptor [13]. Moreover, imatinib mesylate also alters osteoblast
differentiation with promoting [14] or deleterious activities [15]. It
seems that the drug decreases osteoblast proliferation while
stimulating their activity. All published data suggest that imatinib
mesylate may transiently increase osteoblast activity and subse-
quently induce an opposite effect [16]. Based on these observa-
tions, imatinib mesylate may be an interesting drug for bone
sarcoma and especially for osteosarcoma.
The present work aimed to analyze the biological activities of
imatinib mesylate in various human, mouse and rat osteosarcoma
cell lines and on primary tumour growth (at the bone site) using
two different syngenic models of murine osteosarcoma.
Materials and Methods
Ethic Statement
Mice (Elevages Janvier, France) were housed under pathogen-
free conditions at the Experimental Therapy Unit (Faculty of
Medicine, Nantes) in accordance with the institutional guidelines
of the ethical committee and under the supervision of authorized
investigators. The Institutional Animal Care and Use Committee
(CEEA PdL 06) approved specifically the study (authorization
number: 1280.01).
Cells and Culture Conditions
The rat osteosarcoma OSRGA cell line established from a
radio-induced osteosarcoma [17] and human HOS, MG63 cells
purchased from ATCC (Promochem, France) were cultured in
DMEM (Lonza, Belgium) supplemented with 10% FCS (Hyclone,
USA). Murine osteosarcoma POS-1 and MOS-J cells derived from
mouse spontaneous osteosarcoma were provided respectively by
Dr Kamijo [18] and by Dr Shultz [19] and were cultured in RPMI
with 10% FCS. Cells expressed osteoblastic markers more
specifically cbfa1/Runx2, bone alkaline phosphatase, and MOS-
J and OSRGA cells were able to form mineralized nodules in vitro
(data not shown). These parameters were tested before cell
implantation.
Cell Growth, Viability
Two thousand cells per well were plated into 96-well plates and
cultured for 72 h in the presence or absence of imatinib mesylate
(10–40 mM). Cell growth and viability was determined by the
sodium 39[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-me-
thoxy-6-nitro)benzene sulfonic acid hydrate (XTT) cell prolifera-
tion reagent assay kit (Roche Molecular Biomedicals, Germany).
After the culture period and addition of the XTT reagent, the
absorbance was then determined at 490 nm. Caspase activity was
assessed on 10 ml of total cell lysates using the kit CaspACE Assay
System (Promega, USA), following the manufacturer’s recommen-
dations. Results were expressed in arbitrary units and corrected for
protein content quantified using the BCA [bicinchominic acid+
copper(II) sulfate] test (Pierce Chemical Co.). In some experi-
ments, cells were treated with 20 mM of imatinib mesylate in the
presence or the absence of 50 mM of caspase inhibitor N-
benzyloxylcarbonyl-Val-Ala-Asp (OCH3) fluoromethyketone (Z-
VAD-FMK)(Promega, France). Cells treated with 100 nM of
Staurosporin for 24 hours were used as a positive control. Imatinib
mesylate was provided by Pharma Novartis AG (Switzerland).
Time-lapse Microscopy and Wound Healing Assay
Osteosarcoma cells were cultured at 56103cells/mm2 (24-
multiwell plate) in the presence or absence of imatinib mesylate
(10–25 mM). Phase-contrast photos were taken every 10 minutes
for 72 hours through a Leica microscope using a X10 objective
[Leica DMI 6000B (Wetzlar, Germany) coupled with a Coolsnap
HQ2 video camera (Roper Scientific, Evry, France)], then Quick
Time movies were edited with the Metamorph 7.5 software
(Roper Scientific). Cell divisions and dead cells were then
manually scored in each field of observation in a time-dependent
manner. The cells accompanied by extensive plasma membrane
blebbing were considered as apoptotic cells. For wound healing
assay, osteosarcoma cell monolayers were damaged by scraping
with a micropipette tip then incubated for 24 hours in the presence
of 4 mg/mL of mitomycin with or without imatinib mesylate (10–
40 mg/mL). The extent of cell migration into the wounded area
was analyzed by comparing microphotographs after 24 hours of
treatment. Each condition was performed in duplicate.
Cell Cycle Analysis
Sub-confluent OSRGA, MG63, POS-1 or MOS-J cells were
incubated with or without imatinib mesylate (10–25 mM) for 24
hours to 72 hours. After the treatment period, cells were removed
from culture dishes by trypsinization, washed twice in PBS, and
incubated in PBS containing 0.12% of Triton X-100, 0.12 mmol/
L of EDTA, and 100 mg/mL of DNase-free RNase A (Sigma).
Then, 50 mg/ml of propidium iodide were added for 20 minutes at
4uC in the dark. Cell cycle distribution was studied by flow
cytometry (Cytomics FC500, Beckman Coulter,France), based on
2 N and 4 N DNA content and was analyzed by DNA Cell Cycle
Analysis Software (Phoenix Flow System, USA).
Western Blot Analysis
Two hundred thousand osteosarcoma cells were cultured in 6-
multiwell plates and treated with imatinib mesylate (15 or 25 mM)
for 12 hours or 24 hours and then lysed in radioimmunoprecip-
itation assay (RIPA) buffer (150 mM Tris-NaCl, 5% Tris, pH 7.4,
1% NP-40, 0.25% Na deoxycholate, 1 mM Na3VO4, 0.5 mM
PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). In some
experiments, serum-starved osteosarcoma cells were treated with
50 ng/mL PDGF-BB (R&D System) for 5 minutes in the presence
of the absence of 25 mM imatinib mesylate. Cell lysates were
cleared of debris by centrifugation at 12,000 g for 15 minutes.
Protein concentration was determined using the BCA kit (Pierce
Chemical). Twenty mg of total cell lysate proteins were run on 10%
of sodium dodecyl sulfate-poly-acrylamide gel electrophoresis
(SDS-PAGE) and electrophoretically transferred to an Immobilon-
P membrane (Millipore, Bedford, MA, USA). The membrane was
blotted with antibodies to p-mTOR (Ser 2448), p-AKT (Ser 473),
p-ERK1/2 (Thr202/Tyr204), pPDGFRa (Tyr 754), p-PDGFRb
(Tyr 751), p-ERK1/2 (Thr202/Tyr204), actin or the total forms of
protein described above (Table 1) in PBS, 0.05% Tween 20, and
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3% bovine serum albumin (BSA). The membrane was washed and
probed with the secondary antibody coupled to horseradish
peroxidase. Antibody binding was visualized with the enhanced
chemiluminescence system (ECL Kit; Roche Molecular Biomedi-
cals). For quantification, the emitted glow was acquired with a
CCD camera (Syngene, Cambridge, UK) and analyzed with the
GeneTools software (Syngene).
Phospho-Receptor Tyrosine Kinase (RTK) Array
A commercial antibody-based protein microarray designed to
detect 49 human Phospho-receptor tyrosine kinase array kit (R&D
System, UK) was used to identify the molecular targets of imatinib
mesylate. Experiments were carried out following manufacturer’s
instructions. Briefly, array membranes were blocked with the
saturated buffer for 1 hour and then incubated for 2 hours with
HOS osteosarcoma cell lysates treated or not with 50 mM imatinib
mesylate for 45 minutes. After washing, the membranes were
incubated overnight with a specific peroxidase-labeled streptavidin
anti-pTyr antibody. The membranes were then washed, and
detection of immunoreactive spots was revealed by chemilumi-
nescence detection system (GE Healthcare, France). The intensity
of the chemiluminescence was acquired using the ChemiDoc
XRS+ system (BioRad, France). The intensities of the various spot
were determined using Gene Tools software.
RNA Extraction and Semi-quantitative Reverse
Transcription-polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from cultured MG63, HOS, MOS-J,
POS-1 and OSRGA osteosarcoma cells using the TRIzol reagent
(Invitrogen, France). First, RNA was reverse-transcribed (RT),
using 400 U of MMLV-RT from Invitrogen, then 2 ml of the RT
reaction mixture were subjected to PCR using upstream and
downstream primers to determine the expression of human, mouse
and rat PDGFRa/b [30 pmol each, Table 2] and 0.25 ml of 5 U/
ml Taq polymerase (Eurobio, France). PCR products were
analyzed in 1% agarose gels, stained with gel RED and
photographed. Relative expression of the PDGFRa and PGDFRb
genes were compared to the 18S signal and band densities were
measured using the Image Quant computer software program.
After the number of PCR cycles was increased, a plot was done for
each sample, and the cycle value corresponding to the mid of the
linear part of the amplification curve were used to analyse the
expression of the corresponding gene.
Mixed Osteoblastic/Osteolytic Osteosarcoma Model
Four-week-old male C57BL/6J mice were anesthetized by
inhalation of a combination Isoflurane/air associated with an i.m.
injection of Buprenorphine (Temgésic, Schering-Plough) before an
i.m. injection of 46106 MOS-J cells. Tumours appeared in contact
with the tibia approximately 8 days later and led to osteoblastic
lesions reproducing the osteoblastic form of human osteosarcoma
associated with osteolytic foci [7]. Three groups of eight mice each
were assigned as controls (placebo by daily oral administration)
and imatinib mesylate (50 and 100 mg/kg, daily oral administra-
tion) groups. Two types of experiments were carried out: (i)
treatment started one day after tumour cell implantation named
‘‘preventive treatment’’, (ii) treatment started when tumours were
palpable (7–10 days) named ‘‘curative treatment’’.
Undifferentiated Osteosarcoma Model
Four-week-old male C3H/He mice were anesthetized as
previously described before s.c. inoculation of 26106 POS-1 cells
in the hind footpad of the mice. Under these conditions, mice
develop a primary tumour at the site of injection in 3 weeks that
can be transplanted to mice of the same strain as a small fragment
(26262 mm) in close contact with the tibia. For this purpose, the
periostum of the diaphysis was opened and resected along a length
of 5 mm, and the underlying bone was intact. The osteosarcoma
fragment was placed contiguous to the exposed bone surface
without the periostum, and the cutaneous and muscular wounds
were sutured. Tumours appeared at the graft site approximately 8
days later, associated with the development of pulmonary
metastases in a 3-week period. The tumours that developed in
contact with the femora lead to osteolytic lesions that reproduced
the osteolytic form of human osteosarcoma (7, 20). Two groups of
eight mice each were assigned as controls (placebo by daily oral
administration) and 100 mg/kg imatinib mesylate (daily oral
administration) groups. The treatment started one day after
tumour cell implantation.
For both models, the tumour volumes (V) were calculated from
the measurement of two perpendicular diameters using a caliper
according to the following formula: V= 0.56L6S2, where L and S
represent respectively, the largest and smallest perpendicular
tumour diameters. Treatment continued until each animal showed
signs of morbidity including cachexia or respiratory distress, at
which point they were sacrificed by cervical dislocation. Analysis
of architectural parameters was done using high-resolution X-ray
Table 1. Primary antibodies used for cell signaling analysis.
Antibodies and origin Phosphorylated residue Species Dilution
P-PDGFRa Tyr 754 Rabbit 1/1000
PDGFRa Rabbit 1/1000
P-PDGFRb Tyr 751 Rabbit 1/1000
PDGFRb Rabbit 1/1000
P-mTOR Ser 2448 Rabbit 1/1000
mTOR Rabbit 1/1000
P-AKT Ser 473 Rabbit 1/1000
AKT Rabbit 1/1000
P-ERK1/2 Thr202/Tyr204 Rabbit 1/1000
ERK1/2 Rabbit 1/1000
Actin NA Rabbit 1/20000
doi:10.1371/journal.pone.0090795.t001
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micro-computed tomography (CT) (SkyScan-1076). Relative
volume (BV/TV) of the tibia [total bone (cortical+trabecular) or
trabecular bone] was quantified at necropsy on a 3.2 cm length
area located between superior metaphysis and diaphysis. Radio-
graphs were taken at the same time (PLANMED Sophie
apparatus, Finland). Each experiment was repeated twice and
was reproducible. Only one set of experiments was shown.
Statistical Analysis
Each experiment was repeated independently three times in
triplicate. The mean6SD was calculated for all conditions and
compared by ANOVA followed by Bonferroni post hoc test.
Differences relative to a probability of two-tailed p,0.05 were
considered significant.
Results
Imatinib Mesylate Exerts Anti-proliferative Effects on
Human, Mouse and Rat Osteosarcoma Cells
To determine whether imatinib mesylate is able to modulate
viable osteosarcoma cell number, XTT assays have been carried
out for 72 hours in the presence or absence of imatinib mesylate
(1–40 mM). As shown in Figure 1, imatinib mesylate treatment of
human (Figure 1A), mouse (Figure 1B) and rat (Figure 1C)
osteosarcoma cells strongly reduced their viability. Thus, imatinib
mesylate decreased the number of viable osteosarcoma cells in a
dose-dependent manner [IC50 at 72 hours: 20 mM (MG-63),
11 mM (HOS), 23 mM (MOS-J), 15 mM (POS-1); 9 mM
(OSRGA); IC90 at 72 h: 30 mM (MG-63), 19 mM (HOS),
28 mM (MOS-J), 24 mM (POS-1); 16 mM (OSRGA)] with a
maximum effect at 30 mM for most of the cells assessed
(Figure 1D). To determine whether the effects of imatinib mesylate
on osteosarcoma cells resulted from the inhibition of cell
proliferation and/or the induction of cell death, the number of
cell divisions determined by time-lapse microscopy was manually
counted. Time-lapse microscopy revealed that imatinib mesylate
clearly markedly decreases the number of mitosis in a time- and
dose-dependent manner in all cell lines assessed (Figure 2, Figure
S1) (Data not shown for HOS and POS-1 cells). In addition,
imatinib mesylate treatment affected the various cell cycle phases
of all osteosarcoma cells compared to the untreated control
(Figure 3). In MG63, MOS-J and OSRGA cells, imatinib mesylate
induced a cell cyle arrest in G0/G1 phase. Indeed, the number of
cells in G0/G1 phases increased from 62 to 71% for MG63 cells,
from 42 to 52% for MOS-J and from 69 to 82% for OSRGA cells
when treated with imatinib mesylate. The number of cells in S
phase strongly increased from 40 to 65% HOS cells and from 45
to 64% for POS-1 cells when treated with the drug. Concomi-
tantly, the cells in the apoptotic sub-G0/G1 peak also increased in
all cell lines treated (Figure 3).
Imatinib Mesylate Induces Osteosarcoma Cell Death
To determine whether the inhibitory activity of imatinib
mesylate observed in osteosarcoma cell lines was associated with
cell death induction, we used time-lapse microscopy to monitor the
apoptotic events in human, mice and rat osteosarcoma cells
treated with the drug. Time lapse analyses revealed that imatinib
mesylate induced an increase of human, mice and rat osteosar-
coma cell death in a dose-and time-dependant manner (Figure 4,
Figure S2) (Data not shown for HOS and POS-1 cells). The
number of dead/viable cells was also assessed by manual cell
counting based on a trypan blue exclusion assay. Results
confirmed that imatinib mesylate induced cell death of all cell
lines assessed, in a dose-dependent manner (Figure 5A) associated
with a significant increase of caspase activity (Figure 5 B, C). The
pan-caspase inhibitor Z-Vad-FMK partly inhibited the drug-
induced effects on osteosarcoma cell viability as shown for human
MG63 cell line in Figure 5C (p,0.01). Overall, these data
revealed that imatinib mesylate induced apoptosis of all analyzed
osteosarcoma cell lines by a mechanism partly dependent of
caspase activition. In addition, to its functional activity on cell
death, we assessed the effect of imatinib mesylate on cell
migration. As shown in Figure S3, imatinib mesylate strongly
slowed down the migration of human, mouse and rat osteosar-
coma cells. These data demonstrate that imatinib mesylate
therefore exerts cytostatic activity on osteosarcoma.
Table 2. Primer sequences for RT-PCR experiments.
Gene Sequences Size (bp)
Human PDGFRa sens AAG ATA ATG ACT CAC CTG GGG 495
anti-sens AGC CAA AAA CTC CAT TCC TCG
PDGFRb sens AGG TGA TTG AGT CTG TGA GC 630
anti-sens TAT CGT AAG GGG CCA TGT AG
Mouse PDGFRa sens AAG ATA ATG ACT CAC CTG GGG 495
anti-sens AGC CAA AAA CTC CAT TCC TCG
PDGFRb sens AGG TGA TTG AGT CTG TGA GC 630
anti-sens TAT CGT AAG GGG CCA TGT AG
Rat PDGFRa sens CAG GTC TAG TGA GAA GCA AGC TC 382
anti-sens CGA TCT CTG GAT GTC GGA GTA
PDGFRb sens GGT ACG TGT GAA GGT GTC AGA AG 275
anti-sens GGC TCT CCT CCT TGG AAC TAT T
House keeping gene 18S sens TCA AGA ACG AAA GTC GGA GGT TCG 462
anti-sens TTA TTG CTC AAT CTC GGG TGG CTG
doi:10.1371/journal.pone.0090795.t002
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Imatinib Mesylate Inhibits Osteosarcoma Progression
in vivo
In the light of potent inhibitory effects of imatinib mesylate on
human, mice and rat osteosarcoma cell lines in vitro, we next
assessed the effect of the drug on osteosarcoma tumour growth.
Two pre-clinical models of mouse syngenic osteosarcoma have
been used and ‘‘preventive’’ and ‘‘curative’’ treatments have been
tested. The in vivo effects of ‘‘preventive’’ treatments on tumour
growth were first studied in osteolytic POS-1 osteosarcoma model
(Figure 6A,B). Imatinib mesylate reduced significantly in a dose-
dependent manner the tumour volume compared to the control
group (Figure 6A). Rate of tumour progression between days 12
and 21 was also significantly decreased in the treated group
compared to the controls (18566281 mm3 for control mice vs.
6356123 mm3 for daily 100 mg/kg imatinib mesylate treated
mice; p,0.001) (Figure 6B). Similar experiments were carried out
using a mixed osteoblastic/osteolytic MOS-J osteosarcoma model
(Figure 6C,D). All animal treated with imatinib mesylate (n = 8 per
Figure 1. Imatinib mesylate inhibits in a dose dependent
manner the osteosarcoma cells proliferation. Human (HOS,
MG63) (A),mouse (POS-1, MOS-J) (B) and rat (OSRGA) (C) osteosarcoma
cell lines were treated by increasing concentration of imatinib mesylate
(0.1–40 mM) for 72 hours. The number of viable cells was then
determined using an XTT assay. (D) Table summarizing the IC50 and
IC90 of each cell lines studied. Graphs represent the average values of
three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0090795.g001
Figure 2. Inhibitory effect of imatinib mesylate on osteosarco-
ma cell mitosis. Human MG63 (A), mouse MOS-J (B) and OSRGA (C)
osteosarcoma cells were cultured in the presence or absence of
imatinib mesylate with 25 mM, 20 mM and 10 mM respectively. Phase-
contrast photos were taken every 10 minutes for 72 hours and the
number of cell mitosis manually scored in a time-dependent manner.
doi:10.1371/journal.pone.0090795.g002
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Figure 3. Imatinib mesylate affects osteosarcoma cell proliferation by inducing a cell cycle arrest. Cell cycle distribution of human,
mouse and rat osteosarcoma cell lines treated or not with imatinib mesylated for 48 hours was analyzed by propidium iodide staining and flow
cytometry. All experiments were repeated 3 times, and representative results are shown.
doi:10.1371/journal.pone.0090795.g003
Gleevec and Osteosarcoma
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group) exhibited a significant decrease in tumour volume
compared to the control group. In a comparable manner to the
POS-1 model, the studied drug reduced the rate of tumour
progression at days 18 and 43 (Figure 6D). To mimic the clinical
context where tumour was mainly diagnosed in patients when the
tumour mass was detectable, we assessed the ‘‘curative’’ effect of
imatinib mesylate animal treatment started when MOS-J tumours
were palpable (7–10 days) (Figure 6E,F). Although imatinib
mesylate was substantially less effective in the curative regimen
than in the preventive one, hundred mg/kg of compound delayed
the increase in tumour volume consecutively to its first adminis-
tration (Figure 6E). The relative tumour progression calculated
between day 18 and day 43 confirmed the significant inhibitory
effect of imatinib mesylate on osteosarcoma growth
(18786171 mm3 for control mice vs. 12456110 mm3 for
100 mg/kg imatinib mesylate treated mice; p,0.001) (Figure 6F).
We then analyzed the impact of imatinib mesylate on bone
microarchitecture parameters and did not observe significant
effect of the drug on BV/TV and the other bone parameters (data
not shown).
PDGFRa is a Key Target of Imatinib Mesylate in
Osteosarcoma
The functional activity of imatinib mesylate was confirmed by
western blot analysis (Figure 7). Similarly to RAD001, imatinib
mesylate inhibit mTOR pathway in human and murine osteosar-
coma cells (Figure 7A). In contrast to RAD001 for which a
feedback loop takes place in HOS cells (7), imatinib mesylate
markedly abolished Akt phosphorylation (Figure 7A). This
therapeutic association did not reveal any significant synergistic
or additive effect on osteosarcoma cells compared to single
treatments (data not shown). To better identify the main targets of
imatinib mesylate in osteosarcoma, phospho-RTK arrays were
performed in the human HOS cell line. Figure 7B clearly shows
several tyrosine receptor kinases (PDGFRa and PDGFRb, Axl,
RYK, EGFR, EphA2 and 10, IGF1R) as key targets of imatinib
mesylate in HOS cells. In these cells, the phosphorylation status of
these receptors was significantly decreased by imatinib mesylate,
PDGFRa being particularly affected. We then studied the
expression of PDGFRa in the various cell lines studied and
confirmed its expression in human, mouse and rat osteosarcoma
cells (Figure 7C). To confirm the functional activity of PDGFR in
human and murine osteosarcoma cells, the PDGF-BB induced
signaling was investigated (Figure 8). PDGF-BB induced in human
(MG-63, HOS) and murine (POS-1, MOS-J) a rapid phosphor-
ylation of PDGRa and PDFGRb, as well as the downstream
signaling pathways AKT and ERK1/2. The PDGF-BB induced
phosphorylation cascades were markedly inhibited by 25 mM of
imatinib mesylate confirming that both receptors represent
functional targets in osteosarcoma (Figure 8).
Discussion
Whereas metastasis is clearly the lethal process in osteosarcoma
patients, the initial therapeutic response to chemotherapeutic
drugs is a key aspect of the therapeutic care because it predicts the
chance that growth of metastases is inhibited. Indeed, the current
strategy for treatment of high-grade osteosarcoma is based on neo-
adjuvant chemotherapy, delayed en-bloc wide resection, and
adjuvant chemotherapy adapted to the histologic profile assessed
on tumour tissue removed during surgery. The initial therapeutic
response to the first line of chemotherapy will then condition the
following therapeutic lines. Imatinib mesylate is a promising
therapeutic drug targeting a large panel of tyrosine kinase proteins
but also having an effect upon on tyrosine kinase targets such as
quinine oxidoreductase and members of carbonic anhydrase
family of metalloenzymes [21–23]. In this context, we investigated
its effect on osteosarcoma cell lines in vitro and on tumour growth
in vivo. Imatinib mesylate exerts anti-proliferative activities in
human, mouse and rat osteosarcoma cell lines by affecting cell
cycle and inducing caspase-dependent cell death and cell
migration. Murine syngenic models of osteosarcoma have been
Figure 4. Imatinib mesylate increases osteosarcoma cell death.
A kinetic of human (MG63), mouse (MOS-J) and rat (OSRGA)
osteosarcoma cell death was analyzed by time-lapse microscopy in
the presence or the absence of 25 mM, 20 mM or 10 mM imatinib
mesylate respectively. The number of cell death was manually scored
every 10 minutes until 72 hours.
doi:10.1371/journal.pone.0090795.g004
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used to study the efficacy of this therapeutic agent on the primary
tumour growth at the bone site. The data revealed the inhibitory
activity of imatinib mesylate in undifferentiated- and mixed
osteoblastic2/osteolytic forms of osteosarcoma, in ‘‘preventive’’
and ‘‘curative’’ approaches. Finally, PDGFRa, Axl, PDGFRb,
RYK, EGFR, EphA2, EphA10 and IGF1-R are key targets of
imatinib mesylate in osteosarcoma.
Osteosarcomas originate from connective tissues and thus
derive from mesoderm. It has been suggested that osteosarcoma,
chondrosarcoma and Ewing’s sarcoma originate from multipotent
cells called mesenchymal stem cells able to differentiate into
fibroblasts, osteoblasts, chondrocytes, adipocytes etc [1,24–26].
Osteoblasts and their precursors are cellular targets of imatininb
mesylate. Indeed, Indeed, imatinib mesylate inhibits osteoblast
Figure 5. Osteosarcoma cell death induced by imatinib mesylate is partly dependent of caspase activity. (A) Human (MG63, HOS),
mouse (POS-1, MOS-J) and rat osteosarcoma cells were cultured with or without increasing concentrations of imatinib mesylate. After 48 days of
treatment, the alive and dead cells number was manually scored (from trypsinized and floating cells) after trypan blue exclusion. (B) Using similar
culture conditions, caspase-3 activity was assessed using a kit CaspACE Assay System (Promega, USA). (C) On the same way, the involvement of
caspase activity in cell death induced by imatinib mesylate was analyzed using the 2,3-bis(2 methoxy-4 nitro-5-sulfophenyl)2H-tetrazolium-5-
carboxanilide (XTT) assay in the presence or the absence of 50 mM pan-caspase inhibitor Z-Vad-FMK(ZVAD).*p,0.05; ** p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0090795.g005
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proliferation and activity in particular through its inhibitory
activity on PDGFRb [14–16]. We obtained similar findings with
stimulation of calcified matrix deposition by osteoblasts correlating
with modulation of differentiation markers (cbfa1, osteocalcine,
bone sialoprotein) in the presence of low doses of imatinib
mesylate (until 5 mM) while higher doses exert opposite effect with
a strong inhibition of mineral deposit (Figure S4). Such marked
effects of imatinib mesylate on osteoblastic lineage strengthen the
therapeutic interest of imatinib mesylate for osteosarcoma. Ten
years ago, McGary et al demonstrated that imatinib mesylate
inhibits PDGF-mediated growth and leads to osteosarcoma cell
apoptosis in vitro by selective inhibition of the PDGFR [27]. The
effectiveness of the drug was confirmed in murine immunodefi-
cient model of osteosarcoma as revealed by the follow-up of
tumour-associated osteolysis by radiography [28]. Interestingly,
expression of PDGF receptors and their ligands has been
investigated in tissue micro arrays prepared from 54 osteosarcoma
patients. Immunohistochemical analyses showed frequent expres-
sion of PDGFRa and PDGFRb (around 80%) and their ligands
with a correlation with lower event-free survival for PDGFRa that
was not observed for PDGFRb (28). In this context, the patient
PDGFR status may be used as a prognostic marker in
osteosarcoma and may serve to define imatinib mesylate therapy.
Unfortunately, a phase II study of imatinib mesylate in children
with solid tumours demonstrated little of no activity as a single
agent in children with refractory osteosarcoma (10 cases evaluated)
[29]. However, there was no information on the tyrosine kinase
status of patients initially enrolled. Our data revealed that among
the decreased phosphorylated receptors, PDGFRa appears as the
most sensitive target of imatinib mesylate in osteosarcoma. In
Figure 6. Imatinib mesylate inhibits osteosarcoma development in ‘‘preventive’’ and ‘‘curative’’ therapeutic context. Mice bearing
undifferentiated POS-1 (A, B) or mixed osteoblastic/osteolytic MOS-J (C–F) osteosarcoma tumours (n = 8 per group) were assigned as control
(vehicle), or imatinib mesylate (25, 50 or 100 mg/kg, daily oral administration). The treatment started 1 day after tumour cell inoculation (« preventive
» treatment, A–D) or treatment started when tumours are palpable (7–10 days) named ‘‘curative treatment’’ (E, F). Evolution of tumour volumes
(mm3) (A, C, E); follow-up of tumour progressions (B, D, F). * P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0090795.g006
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addition, while all cell lines were sensitive to this drug, PDGFRa
was expressed by all cell lines in contrast to PDGFRb. Our data
are in agreement with the data obtained recently by Kitagawa
et al [30]. These authors studied the specificities of various
approved tyrosine kinase inhibitors including imatinib mesylate,
by activity-based kinase profiling using a panel of 310 human
Figure 7. Imatinib mesylate inhibits AKT/mTOR signaling pathway in osteosarcoma cells and activates ERK1/2 phosphorylation:
PDGFRa, a key target of osteosarcoma cells. Human, mouse and rat osteosarcoma were treated with various doses of imatinib mesylate to
analyse the effects of the drug on intra-cellular signaling pathways. (A) Imatinib mesylate inhibits mTOR and Akt phosphorylation in human HOS and
mouse MOS-J cells. RAD001 named everolimus (RAD), a mTOR inhibitor was used as a positive control. (B) Human Phospho-receptor tyrosine kinase
array Kit was used to identify the molecular targets of imatinib mesylate. (C) Expression of PDGFRa and PDGFRb analyzed in human, mouse and rat
osteosarcoma cells by semi-quantitative RT-PCR.
doi:10.1371/journal.pone.0090795.g007
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recombinant active kinases. They revealed that imatinib mesylate
targets were in rank order of IC50 values: PDFRa, PDFRb,
Discoidin Domain Receptor 2 (DDR2), DDR1, KIT, lymphocyte-
specific protein tyrosine kinase (LCK), yes-related novel PTK B
(LYN B), LYN A and ABL [30].
Our study demonstrated the inhibition of a set of tyrosine kinase
receptors induced by imatinib mesylate (Figure 7). Ten years ago,
from 600 cDNA microarray experiments of human osteosarcoma
cell lines, five genes (Axl, TGFA, COLL7A1, WNT5A, and
MKK6) have been identified and were associated with adherence,
motility, and/or invasiveness of cancer cells [31]. More recently,
using phosphoproteomic screening, Rettew et al identified twelve
receptor tyrosine kinases that were phosphorylated in two
metastatic human osteosarcoma cells (143B, LM7) [32]. In this
extensive screening, these authors identified Axl, EphB2, FGFR2,
IGF-1R and Ret as specific activated receptor tyrosine kinases and
they demonstrated using functional inhibition approaches (neu-
tralizing antibodies, antisense-mediated knockdown or small
molecule inhibitors) that those specific receptors promote the
in vitro behavior of metastatic osteosarcoma cell lines [32]. Axl
appears to be expressed in most osteosarcoma tissues and its
knockdown inhibits proliferation and induces apoptosis of human
osteosarcoma cells [33], its expression predicting the clinical
outcome of patients [34].
Human osteosarcoma also expressed numerous other targets of
imatinib mesylate. Among them, cKit is one of the candidates
[35]. No correlation was found between c-kit expression and
overall or disease-free survival however c-kit-positive tumours
exhibited lower necrosis post-chemotherapy [36]. Similarly the
expression of EphA2 receptors is increased in osteosarcoma and
modulates activation of the mitogenic signalling pathway and
consequently may be involved in the oncogenic process [36]. In
contrast to ephrinB ligands and EphB receptors which regulate the
migration, attachment and spreading of mesenchymal stem cells,
and constitute a bidirectional signaling between osteoclasts and
osteoblasts activating osteoclasts, EphA2 and its ligands act as a
‘‘coupling inhibitor’’ [37]. Indeed, EphA2 reverse signaling into
osteoclasts enhances osteoclastogenesis and suppresses osteoblastic
bone formation. Consequently, EphA2 system may contribute to
the pathogenesis of osteosarcoma by modulating the communica-
tions between tumour cells and their microenvironment [37]. Mass
spectrometry experiments comparing human osteosarcoma cell
lines and human primary osteoblasts identified 156 surface
proteins significantly upregulated on osteosarcoma cells [38].
Among these proteins, EphA2 receptor 2 was the most abundant
surface protein on cancer cells and was expressed in a majority of
human osteosarcoma samples [38]. EphA10 may contribute to the
oncologic process but its role remains under investigation [39].
EGFR and IGF1R have been also identified as therapeutic targets
of tyrosine kinase inhibitors [40,41]. RYK is a tyrosine receptor
interacting with Wnt signalling [42] which strongly contributes to
the dialog between tumour cells and their stromal environment,
especially in osteosarcoma [43,44].
The present data underline the potential therapeutic interest of
imatinib mesylate in osteosarcoma. In light of these data and the
literature, clinical investigations are absolutely required to evaluate
its efficacy according the expression profile of tyrosine kinases
before to conclude on the absence of effectiveness of imatinib
mesylate in osteosarcoma patients. The therapeutic interest of
imatinib mesylate in osteosarcoma then remains an open debate.
Supporting Information
Figure S1 Imatinib mesylate inhibits osteosarcoma cell
divisions in a dose-dependent manner. Human MG63,
mouse MOS-J and rat OSRGA osteosarcoma cells were cultured
in the presence or absence of increasing doses of imatinib
mesylate. Phase-contrast photos were taken every 10 minutes for
72 hours and the number of cell mitosis manually scored in a time-
dependent manner.
(TIF)
Figure S2 Imatinib mesylate induces osteosarcoma cell
death in a dose-dependent manner. A kinetic of human
(MG63), mouse (MOS-J) and rat (OSRGA) osteosarcoma cell
death was analyzed by time-lapse microscopy in the presence or
the absence of increasing doses of imatinib mesylate. The number
of cell death was manually scored every 10 minutes until 72 hours.
(TIF)
Figure S3 Effect of Imatinib mesylate on the osteosar-
coma cell migration. Osteosarcoma cell monolayers were
damaged by scraping with a micropipette tip then incubated for 24
hours in the presence of 4 mg/mL mitomycin with or without
imatinib mesylate (10–40 mg/mL). The extent of cell migration
into the wounded area was analyzed by comparing microphoto-
graphs after 0 and 24 hours.
(TIF)
Figure 8. Imatinib mesylate inhibits the PDGF-BB induced signalling pathways. Human, mouse and rat osteosarcoma were treated with
50 ng/mL of PDGF-BB for 5 minutes in the presence of the absence of 25 mM of imatinib mesylate. PDGFRa, PDGFRb, Akt, ERK1/2 phoshorylations
were analyzed by Western blot compared to the levels of total forms of proteins and the levels of actin.
doi:10.1371/journal.pone.0090795.g008
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Figure S4 Imatinib mesylate exhibits a dual effect on
osteoblast differentiation. Human mesenchymal stem cells
(hMSC) were isolated, cultured, differentiated in osteoblasts and
characterized according the technique described by Lavenus et al
[45]. hMSC were cultured in the presence or absence of increasing
concentrations of imatinib mesylate for 21 days and their ability to
form mineralized matrix in vitro was revealed by alizarin red
staining (A). Osteogenic makers [Runx2 (B), Osteocalcine (C),
Bone Sialo Protein (D)] were followed by quantitative PCR.
Imatinib mesylate exhibits a dual effect on osteoblast differenti-
ation and acts as a pro-osteogenic factor until 5 mM and anti-
osteogenic drug for higher concentrations.
(TIF)
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Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses
osteoclast bone resorbing activity. Eur J Pharmacol 551: 27–33.
14. O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, et al (2007) Imatinib
promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits
osteoclastogenesis by both direct and stromal-cell dependent mechanisms. J Bone
Miner Res 22: 1679–1689.
15. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, et al (2007) Inhibition of
platelet-derived growth factor receptor b by imatinib mesylate suppresses
proliferation and alters differentiation of human mesenchymal stem cells
in vitro. Cell Prolif 40: 355–366.
16. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW (2010)
Dysregulation of bone remodeling by imatinib mesylate. Blood 115: 766–774.
17. Klein B, Pals S, Masse R, Lafuma J, Morin M, et al (1977) Studies of bone and
soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer
20: 112–119.
18. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T (2002) Inhibition of lung
metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh
ligation. Cancer Lett 188: 213–219.
19. Joliat MJ, Umeda S, Lyons BL, Lynes MA, Shultz LD (2002) Establishment and
characterization of a new osteogenic cell line (MOS-J) from a spontaneous
C57BL/6J mouse osteosarcoma. In Vivo 16: 223–228.
20. Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, et al (2007)
Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma:
Blockade of the vicious cycle between tumour cell proliferation and bone
resorption. Cancer Res 67: 7308–7318.
21. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, et al
(2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib,
nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 110:
4055–4063.
22. Winger JA, Hantschel O, Superti-Furga G, Kuriyan J (2009) The structure of
the leukaemia drug imatinib bound to human quinone reductase 2 (NQO2).
BMC Struct Biol 9:7.
23. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, et al (2009) The
protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several
mammalian a-carbonic anhydrase isoforms. Bioorg Med Chem Lett 19: 4102–
4106.
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